Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

Pharm Exec Global Digest: FDA & Social Media Special

July 25, 2014

Will the FDA's social media guidelines help your digital strategy to take off? Check out what they say — and what they mean— in the latest issue of Pharm Exec Global Digest

WebMD: The Patient Value Equation

July 10, 2014

WebMD CEO David Schlanger tells PharmExec how connecting patients with physicians through a robust digital platform can deliver quality of care, cost savings, and better health outcomes.

Pre-emption and States' Rights

July 23, 2014

Pharma backs federal standards for compassionate use, drug importing, data transparency, and track-and-trace. Jill Wechsler reports.

Breaking Point? The Escalating Costs of Oncology Care in the US

July 17, 2014

The US healthcare system will spend more than $150 billion on cancer by 2020. Daniele Severi Bruni, Jacob Schutz, and Anthony Hewitt ask if we have we have hit a breaking point in the escalating cost of oncology care.

Fixing the Disconnect in Medical Technology

July 16, 2014

The med-tech industry has a legacy of creating life-extending products while rewarding investors. This connection between innovation and profitability has been a key driver. But, writes Doug Mowen, change is underway.

Vaccines: Fire in the Cold Chain

July 10, 2014

Its only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance.

The Peace Dividend

July 10, 2014

A surprising takeaway from the recent BIO Convention, writes William Looney, is the stark contrast between cooperative industry engagement and an unstable geopolitical order.

Pharm Exec's 2014 Dealmakers Outlook

July 10, 2014

As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead for M&A, licensing, and partnership activity.

Capturing the Real Value from a Pharma Spinout

July 9, 2014

The pharma spin market is moving up a gear as companies see the imperative to tap into brand value. Allen Gove explains how understanding what the company is about is critical to bolstering the value of the product.

ADVERTISEMENT

Click here